Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $221,247.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $1,005,164.10. This represents a 18.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Travere Therapeutics Trading Up 4.8 %

Shares of TVTX stock opened at $19.06 on Wednesday. The stock has a 50-day simple moving average of $16.85 and a 200 day simple moving average of $11.52. The stock has a market capitalization of $1.49 billion, a P/E ratio of -4.19 and a beta of 0.70. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $20.33. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.17) EPS. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -3.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TVTX. Citigroup lowered their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Leerink Partners restated an “outperform” rating and issued a $20.00 price target on shares of Travere Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reduced their price objective on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Canaccord Genuity Group decreased their price objective on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a report on Monday, September 30th. Finally, Scotiabank lifted their target price on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.62.

Institutional Trading of Travere Therapeutics

Large investors have recently added to or reduced their stakes in the business. EntryPoint Capital LLC bought a new position in shares of Travere Therapeutics in the first quarter valued at $32,000. CWM LLC grew its holdings in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares during the last quarter. DRW Securities LLC acquired a new stake in shares of Travere Therapeutics during the second quarter worth $95,000. Quarry LP purchased a new stake in shares of Travere Therapeutics during the third quarter valued at $105,000. Finally, Forefront Analytics LLC boosted its position in shares of Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.